Emerging Infections
For any questions or information, please email covidrapidreviewteam@gmail.com.
Pediatric Transmission (Abridged Version 1) PMI MCM
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Fatty acid Abridged 15May2020
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Mesenchymal Stem Cell Abridged 13May2020
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Arbidol_Abridged_10May2020_version1_KLR,AFM
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Zinc prophy_Abridged_report_V1 20 APRIL LFD_RFG BLD
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
HFNC NIV Abrdiged (26 April 2020) v1.2 CAV
The Philippine Society for Microbiology and Infectious Diseases (PSMID) Guidance on the Management of Mpox, Ver. 1 provides the basic and most updated information on management of patients confirmed with mpox.
This guidance complements the mpox recommendations of the DOH (Updated Interim Guidelines on the Prevention, Detection, and Management of MPOX, by Department of Health, August 26, 2024, Department Memorandum 2024-0306) and PHICS-PHICNA (Interim Guidelines on the Prevention and Control of Monkeypox version 1).
The antivirals, immunoglobulin and vaccines discussed below are not available locally. In our local situation, we should maximize supportive care for mpox cases.